Amneal Pharmaceuticals, Inc. - News - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Dec 30, 2003

IMPAX Comments on Shire's Lawsuit Related to Generic Version of Adderall XR

Dec 24, 2003

IMPAX Receives FDA Tentative Approval for Generic Versions Of OxyContin; Ninth ANDA Approval in 2003

Dec 04, 2003

IMPAX to Present at First Albany Growth Conference

Nov 30, 2003

MPAX Receives FDA Approval for Generic Claritin Reditabs

Nov 19, 2003

IMPAX ANDA Filing for Generic Version of Adderall XR Accepted by FDA

Nov 18, 2003

IMPAX Added to NASDAQ Biotech Index Effective November 24, 2003

Nov 09, 2003

IMPAX Comments on Alza's Lawsuit Related to Generic Version Of Ditropan XL

Nov 05, 2003

IMPAX Receives FDA Tentative Approval for Generic Versions Of OxyContin; Ninth ANDA Approval in 2003

Nov 05, 2003

IMPAX Reports Third Quarter Financial Results; Company Continues to Post Record Quarterly Revenues; Four FDA Approvals Received in the Quarter

Nov 04, 2003

IMPAX to Present at CIBC World Markets Annual Healthcare Conference

Nov 02, 2003

IMPAX Receives FDA Approval for Generic Aralen

Oct 28, 2003

IMPAX Receives Final FDA Approval for Fenofibrate Capsules ANDA; Eighth ANDA Approval of 2003 for IMPAX

Oct 27, 2003

IMPAX Settles Patent Suit Related to Claritin-D 24-Hour

Oct 27, 2003

IMPAX Laboratories To Hold Third Quarter 2003 Financial Results Conference Call Wednesday, November 5, 2003

Oct 03, 2003

IMPAX Appoints Deloitte & Touche LLP as Independent Auditors

Aug 29, 2003

IMPAX Receives FDA Approval for Generic Urispas

Aug 04, 2003

IMPAX Announces Favorable Decision in Claritin Patent Appeal

Jul 31, 2003

IMPAX Signs Agreement With ANDRX and Teva for Generic Formulations of Wellbutrin® SR and ZYBAN®

Jul 28, 2003

IMPAX Reports Second Quarter Financial Results

Jul 22, 2003

IMPAX Laboratories to Hold Second Quarter 2003 Financial Results Conference Call Monday, July 28, 2003

Jun 17, 2003

IMPAX to Present at 13th Annual Wachovia Securities Nantucket Conference

May 28, 2003

IMPAX ANDA Filing for Generic Version of Wellbutrin SR® 200mg Tablets Accepted by FDA

May 19, 2003

IMPAX Shareholders Re-Elect Board Members

May 07, 2003

IMPAX Announces $25 Million Private Placement

Apr 30, 2003

IMPAX Reports Record First Quarter Results

Apr 28, 2003

IMPAX Receives FDA Approval for Generic Mestinon

Apr 24, 2003

IMPAX to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference

Apr 23, 2003

IMPAX Laboratories to Hold First Quarter 2003 Financial Results Conference Call Wednesday, April 30, 2003

Apr 09, 2003

IMPAX Announces Merck's Withdrawal of Lawsuit Related to Generic Version of Sinemet CR

Mar 28, 2003

IMPAX Prevails in Tricor Capsules Patent Infringement Suit

Mar 19, 2003

IMPAX to Present at Banc of America Healthcare Conference

Feb 28, 2003

IMPAX to Present at Lehman Brothers Global Healthcare Conference

Feb 24, 2003

IMPAX Comments on Merck's Lawsuit Related to Generic Version of Sinemet CR

Feb 12, 2003

IMPAX Reports Record Revenues in the Fourth Quarter and the Year 2002

Feb 05, 2003

IMPAX Laboratories to Hold Fourth Quarter & Year-End 2002 Financial Results Conference Call Wednesday, February 12, 2003

Jan 31, 2003

IMPAX Receives Final FDA Approval for a Generic Version of Claritin-D 12-Hour

Jan 30, 2003

IMPAX Receives FDA Approval for Generic Rilutek

Jan 27, 2003

IMPAX Comments on Abbott's Lawsuit Related to Generic Version Of Tricor

Jan 21, 2003

IMPAX Appoints Peter Terreri to Its Board of Directors

Jan 03, 2003

IMPAX Appoints Michael Wokasch Chief Operating Officer

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.35.1.5